In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Pacira BioSciences Inc (NASDAQ: PCRX) closed at $21.88 in the last session, up 6.47% from day before closing price of $20.55. In other words, the price has increased by $6.47 from its previous closing price. On the day, 0.81 million shares were traded. PCRX stock price reached its highest trading level at $22.08 during the session, while it also had its lowest trading level at $20.33.
Ratios:
We take a closer look at PCRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.22. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 2.25. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when SLONIN JONATHAN sold 879 shares for $18.40 per share. The transaction valued at 16,174 led to the insider holds 93,444 shares of the business.
SLONIN JONATHAN bought 879 shares of PCRX for $16,174 on Jan 06 ’25. On Dec 13 ’24, another insider, GAUGLER DARYL, who serves as the Chief Operating Officer of the company, sold 500 shares for $19.76 each. As a result, the insider received 9,880 and left with 115,200 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1010269568 and an Enterprise Value of 1200883456. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.45 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 1.728 whereas that against EBITDA is 6.745.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.75, which has changed by -0.3523479 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $34.01, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 18.88%, while the 200-Day Moving Average is calculated to be 4.50%.
Shares Statistics:
According to the various share statistics, PCRX traded on average about 698.00K shares per day over the past 3-months and 700340 shares per day over the past 10 days. A total of 46.15M shares are outstanding, with a floating share count of 44.70M. Insiders hold about 3.19% of the company’s shares, while institutions hold 112.34% stake in the company. Shares short for PCRX as of 1735603200 were 4364176 with a Short Ratio of 6.25, compared to 1732838400 on 4795767. Therefore, it implies a Short% of Shares Outstanding of 4364176 and a Short% of Float of 13.76.
